Australia Richard Day of the University of New South Wales, writing in the October 2023 edition of DIA’s Global Forum magazine, looks at updates to the health technology assessment (HTA) processes in Australia and New Zealand In April 2023, the Australian Department of Health and Aged Care launched an independent Health…
Australia After last year’s acquisition of Vifor Pharma, the firm’s largest ever, opened new avenues for diversification, the ground-breaking approval of the Hemgenix gene therapy for Hemophilia B was an equally significant moment for the company. New CEO Paul MacKenzie continues to pursue further growth for Australia’s largest biopharma company, investing…
Global CSL, Australia’s largest biopharma company, overcame the challenges of the pandemic-related decline in plasma collection and has since racked up wins such as the acquisition of Vifor, the largest in the company’s history, and the FDA approval of its gene therapy for haemophilia B. Newly appointed CEO Paul McKenzie takes…
Australia A roundup of some of the latest news from Australian pharma, including CSL’s unification of business units, a workers strike at Pfizer’s manufacturing plant, a new USD 173 million research centre, and a billionaire’s bet on biotech. New $173M research centre for pandemic drug discovery (Endpoints News) In the…
Australia With one of the best healthcare systems in the world, according to the World Health Organisation (WHO), Australia is home to some 250 global and local reasearch-based pharmaceutical companies and ranks 13th in the global share of pharmaceutical patents. Value of the market: Economic footprint of the industry: Acquistions of…
Asia-Pacific Writing in the June edition of DIA’s Global Forum magazine, Ellen Sem, Fengyun (Vicky) Han and Annetta C. Beauregard from Janssen Pharmaceutical Companies of Johnson & Johnson, outline the real-world data (RWD) and real-world evidence (RWE) regulatory landscape in Asia Pacific. Real-world data (RWD) and real-world evidence (RWE) have played an…
Australia Pharmaceutical policy issues played a major role in Australia’s recent national election. Shawview Consulting’s Brendan Shaw outlines the medicines issues that came under scrutiny during the campaign. It was the first national election since the start of the COVID-19 pandemic, and it resulted in an historic change of government. The…
Australia Writing in April edition of DIA’s Global Forum magazine, the University of New South Wales’s Richard Day looks at Australia’s National Medicines Policy (NMP) and how it is being reshaped by community and stakeholder feedback. Australia’s National Medicines Policy (NMP), gazetted in 2000, is being revised and the draft policy was…
Australia Writing in the January edition of DIA’s Global Forum magazine, Julia Chan, David Liew, Jana Stojanova, and Chris McMaster of Austin Health, Melbourne and St. Vincent’s Hospital Sydney outline how artificial intelligence (AI) solutions can best be applied to pharmacovigilance in Australia, and the challenges that stand ahead. For…
Australia Australia’s international outlook, strong science base, multi-ethnic English-speaking population and high educational and regulatory standards make it an attractive location to undertake clinical trials for medicines and vaccines. These fundamentals were foregrounded during the COVID-19 pandemic, when Australia was able to pivot quickly and develop capabilities in technology and tele-monitoring…
Australia In conversation in the November issue of DIA’s Global Forum magazine, Australian Pharmaceutical medical and scientific Professionals Association (APPA) Past President David Grolman highlights the contributions that Australia is already making to the global innovative pharmaceutical industry and why his country remains a particularly attractive clinical trials hub. “We…
Global As our thoughts here at PharmaBoardroom turn towards the summer holidays, we are happy to share the five most-read articles from our global contributor network so far in 2021. These thought leadership pieces cover topics as vital and diverse as the latest regulatory updates from China; EU-UK pharma trade; the…
See our Cookie Privacy Policy Here